The aims of this study were to assess the prevalence and type of activating point mutations at codons 12, 13, and 61 of the Ki-, Ha-, and N-ras The human ras proto-oncogene family includes the homologous Ha-, Ki-, and N-ras genes, which code for closely related 21 kDa proteins (p21ras). These proteins, located at the inner cell membrane, can bind GDP and GTP and possess intrinsic GTP-ase activity
type). H pylorn was found in the antral mucosa of 28 early gastric carcinomas (62%). Activating ras gene mutations were not found. It was discovered that activating point mutations at codons 12, 13, and 61 of the Ki-, Ha-, and N-ras genes do not play a part in the development of early gastric carcinomas in white subjects, irrespective of The human ras proto-oncogene family includes the homologous Ha-, Ki-, and N-ras genes, which code for closely related 21 kDa proteins (p21ras). These proteins, located at the inner cell membrane, can bind GDP and GTP and possess intrinsic GTP-ase activity.1
Activation of the ras genes can be due to gene amplification with enhanced expression of p21ras proteins.2 Activation is usually caused by point mutations at codons 12, 13, or 61 of the ras genes, however, which confer transforming properties to these proto-oncogenes. As these mutations are all localised to or near the GTP-binding domain, the intrinsic GTP-ase activity of the p2 1 ras proteins is nearly 100% reduced and the p21ras proteins persist in their biologically active, GTP-bound state. This, in turn, leads to a continuous signal transduction, even in the absence of an external stimulus. 3 Point mutations in the Ki-ras gene are uniformly reported to 46 Presumably, a moderate increase in ras gene expression is therefore related to active cell proliferation rather than to malignant phenotype. Thirdly, although overexpression of wild-type p21ras has been implicated in malignant transformation,2 47 48 this mechanism is generally considered to be a rare event in tumorigenesis. Fourthly, inherent pitfalls of most p21ras antibodies hamper a correct interpretation of immunohistochemical studies.49 Therefore, in view of the above and in view of the absence of activating ras gene mutations in our series, we feel that ras gene abnormalities in all probability do not contribute to gastric carcinogenesis and in all probability do not contribute to the concept of a different pathogenesis of both Lauren types.
To date, the role of H pylori in gastric carcinogenesis is a topic of great interest. Whereas many studies have been published that suggest a role for H pylori in this process, no studies so far have reported on the difference in molecular make up, if any, between H pylori positive and H pylori negative gastric carcinomas. A pitfall of retrospective studies in classifying carcinomas into H pylorn positive and H pylori negative cases is that extensive intestinal metaplasia formation, particularly in the course of the carcinogenic process of intestinal-type carcinomas may have led to the disappearance of the micro-organism in the stomach, resulting in an underestimation of its prevalence. Moreover, previous use of antibiotics may also have confounded results. Nevertheless, as ras gene mutations were completely absent in our series, it may be assumed that H pylori positive and H pylori negative gastric carcinomas cannot be discriminated on the basis of ras gene mutational analysis.
Despite the excellent prognosis of surgically treated early gastric carcinomas compared with advanced gastric carcinomas, the metastatic potential and postoperative five year survival rate of early gastric carcinomas seem to be correlated with the type of growth pattern. In particular, the penetrating A type, in contrast with the other growth types, has been reported to have a high propensity for blood vessel invasion and lymph node metastasis and to have the worst prognosis after surgery because of early postoperative hepatic metastasis.26 In a related study we showed that this apparent difference in clinical or biological behaviour, or both, could not be explained on the basis of a difference in nuclear p53 protein accumulation.50 This study shows that ras gene mutations do not underlie these clinical findings either.
In conclusion, activating point mutations at codons 12, 13, and 61 of the Ha-, Ki-, and N-ras genes do not play a part in the development of (early) gastric carcinomas of white subjects irrespective of Lauren type. Moreover, these ras gene mutations do not underlie the differences in clinical or biological behaviour, or both, of early gastric carcinomas with different types of growth pattern. Finally, H pylori positive and H pylori negative gastric carcinomas cannot be discriminated by ras gene mutational analysis. 
